Gufic Biosciences Limited has released its comprehensive investor presentation covering unaudited financial results for Q3FY26, following its scheduled earnings conference call on February 16, 2026. The pharmaceutical company shared detailed insights into its quarterly performance and strategic initiatives across multiple business segments.

Q3FY26 Financial Performance

The company reported total revenue of ₹231.10 crore for Q3FY26, representing an increase from ₹207.80 crore in Q3FY25. However, profitability metrics showed some moderation compared to the previous year.

Nine-Month Performance Overview

For the nine months ended December 31, 2025, Gufic Biosciences achieved total revenue of ₹688.40 crore compared to ₹614.80 crore in the corresponding period of the previous year.

Indore Facility Progress Update

The company provided significant updates on its advanced lyophilized injectable facility at Indore, which commenced production in October 2024. The facility is designed to meet WHO GMP, EU GMP, ANVISA, MHRA, and USFDA standards with substantial manufacturing capacity.

The facility has achieved 30% capacity utilization for FY26 and is on track for EBITDA breakeven. The company has completed performance qualification for all lines, media fills for sterility validation, and received 203 product permissions from State FDA to date.

Business Platform Performance

Gufic Biosciences operates through multiple specialized platforms including Hospital Injectable Platform focusing on anti-microbials and cardiac critical care, Women's Health Platform covering assisted reproductive technology, and Botulinum Toxin Platform for aesthetics and neurology applications. The company continues to strengthen its presence in critical care divisions and infertility segments while expanding its international business footprint.

Regulatory and Compliance Updates

The investor presentation was formally communicated to BSE Limited and National Stock Exchange of India Limited on February 13, 2026, pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Whole Time Director Pankaj Gandhi signed the official communication to both exchanges, ensuring compliance with regulatory requirements.

Gufic biosciences Limited has received an income tax demand notice of ₹4.33 crores for Assessment Year 2024-25, the pharmaceutical company informed stock exchanges on January 20, 2026. The demand was issued under Section 156 of the Income Tax Act, 1961, following a computation under Section 143(1)(a) due to disallowance of expenditure.

Tax Demand Details

The Income Tax Department raised the demand aggregating to ₹4,33,36,680 based on expenditure disallowances during the assessment process. The company received the order dated December 22, 2025, on January 19, 2026, and promptly disclosed the information to comply with SEBI listing regulations.

Company's Response Strategy

Gufic Biosciences plans to challenge the tax demand through the appellate process. The company intends to file an appeal before the Commissioner of Income Tax (Appeal) within the time limit prescribed under the Income Tax Act. Management expressed confidence in achieving a favorable outcome based on the case merits, prevailing law, and advice from tax advisors.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided comprehensive details as required under the SEBI Master Circular dated November 11, 2024, ensuring transparency with stakeholders regarding the tax proceedings.

Financial Impact Assessment

While the demand represents a significant amount, the company's assessment suggests potential for successful appeal. Gufic Biosciences emphasized that based on legal advice and case merits, they remain hopeful of a favorable resolution at the appellate authority level. The company will continue to monitor the proceedings and keep stakeholders informed of any material developments.